YM BioSciences

From Wikipedia, the free encyclopedia

YM BioSciences (TSX: YM) is a biotech company towards finding cancer cures. Its recent work includes EGF receptor monoclonal antibody called TheraCIM hR3, which has been given orphan status by the Food and Drug Administration (FDA). It is targeted to treatment of gliomas. TheraCIM hR3, nimotuzumab, is currently undergoing two Phase II trials in Europe and is expected to become a Phase III candidate in early 2005.

[edit] External links

Official site

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

Categories: Companies listed on the Toronto Stock Exchange | Biotechnology | Medical company stubs

Views

Interaction

Search

Powered by MediaWiki

Wikimedia Foundation

This page was last modified 16:51, 22 December 2007 by Wikipedia user SmackBot. Based on work by Wikipedia user(s) Mlaffs, Ebyabe, Alaibot, Bluebot, Epolk, TPO-bot, Kaihsu, Aecis, Everyking, Jfdwolff, Viriditas and Vogon77.
All text is available under the terms of the GNU Free Documentation License. (See Copyrights for details.)
Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a U.S. registered 501(c)(3) tax-deductible nonprofit charity.
About Wikipedia
Disclaimers